|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CFTR |
Gene summary for CFTR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CFTR | Gene ID | 1080 |
| Gene name | CF transmembrane conductance regulator | |
| Gene Alias | ABC35 | |
| Cytomap | 7q31.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R730 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1080 | CFTR | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.64e-30 | -7.59e-01 | 0.0155 |
| 1080 | CFTR | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.66e-07 | -5.59e-01 | -0.1808 |
| 1080 | CFTR | HTA11_2951_2000001011 | Human | Colorectum | AD | 9.26e-12 | -1.14e+00 | 0.0216 |
| 1080 | CFTR | HTA11_78_2000001011 | Human | Colorectum | AD | 6.15e-08 | 2.88e-01 | -0.1088 |
| 1080 | CFTR | HTA11_347_2000001011 | Human | Colorectum | AD | 2.87e-11 | 6.95e-01 | -0.1954 |
| 1080 | CFTR | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.04e-02 | -6.21e-01 | -0.2196 |
| 1080 | CFTR | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.13e-30 | -1.21e+00 | -0.1207 |
| 1080 | CFTR | HTA11_83_2000001011 | Human | Colorectum | SER | 4.00e-03 | -1.12e-01 | -0.1526 |
| 1080 | CFTR | HTA11_696_2000001011 | Human | Colorectum | AD | 1.44e-16 | -5.56e-01 | -0.1464 |
| 1080 | CFTR | HTA11_866_2000001011 | Human | Colorectum | AD | 5.48e-06 | -3.01e-01 | -0.1001 |
| 1080 | CFTR | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.32e-02 | -2.93e-01 | -0.059 |
| 1080 | CFTR | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.87e-08 | -7.74e-01 | -0.2061 |
| 1080 | CFTR | HTA11_866_3004761011 | Human | Colorectum | AD | 2.55e-05 | -3.35e-01 | 0.096 |
| 1080 | CFTR | HTA11_4255_2000001011 | Human | Colorectum | SER | 2.03e-03 | -6.17e-01 | 0.0446 |
| 1080 | CFTR | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.65e-02 | -6.26e-01 | 0.0451 |
| 1080 | CFTR | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.03e-07 | -7.73e-01 | 0.0528 |
| 1080 | CFTR | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.06e-04 | -4.86e-01 | 0.0338 |
| 1080 | CFTR | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.07e-06 | -3.40e-01 | 0.0674 |
| 1080 | CFTR | HTA11_11156_2000001011 | Human | Colorectum | AD | 1.24e-04 | -1.02e+00 | 0.0397 |
| 1080 | CFTR | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.46e-02 | 1.95e-01 | 0.0588 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:1902653 | Liver | Cirrhotic | secondary alcohol biosynthetic process | 34/4634 | 57/18723 | 2.22e-08 | 7.77e-07 | 34 |
| GO:000974312 | Liver | Cirrhotic | response to carbohydrate | 101/4634 | 253/18723 | 6.24e-08 | 1.92e-06 | 101 |
| GO:003428412 | Liver | Cirrhotic | response to monosaccharide | 90/4634 | 225/18723 | 2.87e-07 | 7.01e-06 | 90 |
| GO:000974612 | Liver | Cirrhotic | response to hexose | 86/4634 | 219/18723 | 1.30e-06 | 2.59e-05 | 86 |
| GO:009730512 | Liver | Cirrhotic | response to alcohol | 96/4634 | 253/18723 | 1.97e-06 | 3.65e-05 | 96 |
| GO:00097497 | Liver | Cirrhotic | response to glucose | 82/4634 | 212/18723 | 4.54e-06 | 7.51e-05 | 82 |
| GO:00224065 | Liver | Cirrhotic | membrane docking | 39/4634 | 86/18723 | 2.47e-05 | 3.22e-04 | 39 |
| GO:19016551 | Liver | Cirrhotic | cellular response to ketone | 42/4634 | 96/18723 | 3.55e-05 | 4.32e-04 | 42 |
| GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
| GO:0046165 | Liver | Cirrhotic | alcohol biosynthetic process | 55/4634 | 140/18723 | 9.74e-05 | 1.03e-03 | 55 |
| GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
| GO:19016171 | Liver | Cirrhotic | organic hydroxy compound biosynthetic process | 81/4634 | 237/18723 | 6.73e-04 | 5.06e-03 | 81 |
| GO:01400565 | Liver | Cirrhotic | organelle localization by membrane tethering | 32/4634 | 77/18723 | 8.65e-04 | 6.23e-03 | 32 |
| GO:00713336 | Liver | Cirrhotic | cellular response to glucose stimulus | 55/4634 | 151/18723 | 8.93e-04 | 6.41e-03 | 55 |
| GO:005159112 | Liver | Cirrhotic | response to cAMP | 37/4634 | 93/18723 | 9.58e-04 | 6.78e-03 | 37 |
| GO:000167812 | Liver | Cirrhotic | cellular glucose homeostasis | 61/4634 | 172/18723 | 1.06e-03 | 7.40e-03 | 61 |
| GO:004259312 | Liver | Cirrhotic | glucose homeostasis | 86/4634 | 258/18723 | 1.12e-03 | 7.73e-03 | 86 |
| GO:00713316 | Liver | Cirrhotic | cellular response to hexose stimulus | 55/4634 | 153/18723 | 1.27e-03 | 8.56e-03 | 55 |
| GO:003350012 | Liver | Cirrhotic | carbohydrate homeostasis | 86/4634 | 259/18723 | 1.28e-03 | 8.61e-03 | 86 |
| GO:001591811 | Liver | Cirrhotic | sterol transport | 48/4634 | 130/18723 | 1.32e-03 | 8.83e-03 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
| hsa05110 | Colorectum | AD | Vibrio cholerae infection | 29/2092 | 50/8465 | 5.10e-07 | 7.12e-06 | 4.54e-06 | 29 |
| hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
| hsa04971 | Colorectum | AD | Gastric acid secretion | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
| hsa04972 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
| hsa045301 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
| hsa051101 | Colorectum | AD | Vibrio cholerae infection | 29/2092 | 50/8465 | 5.10e-07 | 7.12e-06 | 4.54e-06 | 29 |
| hsa041521 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
| hsa049711 | Colorectum | AD | Gastric acid secretion | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
| hsa049721 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
| hsa045302 | Colorectum | SER | Tight junction | 59/1580 | 169/8465 | 3.24e-07 | 5.98e-06 | 4.34e-06 | 59 |
| hsa051102 | Colorectum | SER | Vibrio cholerae infection | 24/1580 | 50/8465 | 2.17e-06 | 3.13e-05 | 2.28e-05 | 24 |
| hsa049712 | Colorectum | SER | Gastric acid secretion | 27/1580 | 76/8465 | 3.65e-04 | 3.27e-03 | 2.38e-03 | 27 |
| hsa049722 | Colorectum | SER | Pancreatic secretion | 30/1580 | 102/8465 | 5.41e-03 | 3.28e-02 | 2.38e-02 | 30 |
| hsa045303 | Colorectum | SER | Tight junction | 59/1580 | 169/8465 | 3.24e-07 | 5.98e-06 | 4.34e-06 | 59 |
| hsa051103 | Colorectum | SER | Vibrio cholerae infection | 24/1580 | 50/8465 | 2.17e-06 | 3.13e-05 | 2.28e-05 | 24 |
| hsa049713 | Colorectum | SER | Gastric acid secretion | 27/1580 | 76/8465 | 3.65e-04 | 3.27e-03 | 2.38e-03 | 27 |
| hsa049723 | Colorectum | SER | Pancreatic secretion | 30/1580 | 102/8465 | 5.41e-03 | 3.28e-02 | 2.38e-02 | 30 |
| hsa045304 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
| hsa051104 | Colorectum | MSS | Vibrio cholerae infection | 27/1875 | 50/8465 | 8.58e-07 | 1.20e-05 | 7.34e-06 | 27 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CFTR | SNV | Missense_Mutation | c.311N>C | p.Arg104Thr | p.R104T | P13569 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CFTR | SNV | Missense_Mutation | c.3568N>C | p.Val1190Leu | p.V1190L | P13569 | protein_coding | tolerated(0.27) | benign(0.156) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CFTR | SNV | Missense_Mutation | rs397508381 | c.2476G>A | p.Glu826Lys | p.E826K | P13569 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CFTR | SNV | Missense_Mutation | novel | c.3460G>A | p.Asp1154Asn | p.D1154N | P13569 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CFTR | SNV | Missense_Mutation | c.3758N>C | p.Leu1253Ser | p.L1253S | P13569 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CFTR | SNV | Missense_Mutation | c.1345N>C | p.Glu449Gln | p.E449Q | P13569 | protein_coding | tolerated(0.06) | benign(0.337) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CFTR | SNV | Missense_Mutation | c.1775G>T | p.Cys592Phe | p.C592F | P13569 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0DV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR | |
| CFTR | SNV | Missense_Mutation | c.2771N>G | p.Asp924Gly | p.D924G | P13569 | protein_coding | tolerated(0.11) | benign(0.378) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CFTR | SNV | Missense_Mutation | c.4273G>T | p.Asp1425Tyr | p.D1425Y | P13569 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CFTR | SNV | Missense_Mutation | novel | c.453G>C | p.Gln151His | p.Q151H | P13569 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | ivacaftor / tezacaftor | |||
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | elexacaftor / tezacaftor / ivacaftor | |||
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | VX-809 | LUMACAFTOR | ||
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | lumacaftor | LUMACAFTOR | 22698459,24561283,26137539,24038832,22293084,24973281,21825083,24392786,26823392,28325531,24796242,27334259,21976485,23891399 | |
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | blocker | 178101015 | ||
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | 187051756 | CROFELEMER | |
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | ABBV-2451 | |||
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | activator | 53801090 | CAPSAICIN | |
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | IVACAFTOR | IVACAFTOR | ||
| 1080 | CFTR | DRUGGABLE GENOME, ABC TRANSPORTER, ION CHANNEL, TRANSPORTER, CELL SURFACE, CLINICALLY ACTIONABLE | activator | 178101101 |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |